Entity family

Browse funders

Organisations named as supporting, sponsoring, or funding research. Examples include Wellcome, NIHR, research councils.

3articles mentioning funders

3funder mentions

1distinct funders extracted

0%of mentions human-reviewed

Active filtersEntity: NCT06598371 ×

NCT06598371

This funder is selected. Its supporting articles are shown below.

NCT065983713

Articles mentioning NCT06598371

3 articles · page 1 of 1

253 eCARTM-T: dual-inactivation of SOCS1 and regnase-1 by CRISPR/Cas9 gene editing enhances CAR-T function against solid tumors

jitc · abstract · 2025-11-04 · 1 matching annotations

93.3%

NCT06598371 solid tumors hematological cancers KSQ-004EX hematologic cancers

…IL®) therapy KSQ-004EX, currently in a phase 1 clinical trial ( NCT06598371). Here, we investigate the impact of inactivating Regnase-1 and…

383 SOCS1 and regnase-1 inactivation enhances functionality and prevents exhaustion of tumor reactive clonotypes in KSQ-004EX eTIL

jitc · abstract · 2025-11-04 · 1 matching annotations

88.5%

NCT06598371 solid tumors KSQ-004EX Tumor Infiltrating Lymphocyte (TIL) therapy tumor

…ng evaluated in a clinical trial for treatment of solid tumors (NCT06598371). Here, we interrogated the impact of SOCS1 and Regnase-1 inact…

569 A phase 1/2 study of KSQ-004EX: autologous tumor infiltrating lymphocytes, engineered to inactivate genes encoding SOCS1 and regnase-1, in patients with select advanced solid tumors

jitc · abstract · 2025-11-04 · 1 matching annotations

82.5%

NCT06598371 melanoma cervical cancer KSQ-004EX NSCLC pancreatic cancer IL-2 CRC colorectal carcinoma non-small cell lung cancer

…, persistence, and efficacy.This first-in-human clinical study (NCT06598371) evaluates KSQ-004EX in patients with melanoma, non-small cell …